Porton Wins “2025 Best CRO” Award from Daewoong Pharma

Recently, Porton Pharma Solutions Ltd. has received the 2025 Best CRO awarded from South Korea’s Daewoong Pharmaceutical Co., Ltd. (hereinafter referred to as "Daewoong Pharma"). This award recognizes Porton’s outstanding performance in the early R&D, manufacturing and delivery of innovative drug APIs, as well as its high-quality service capabilities, and directly reflects the fruitful results of cooperation between the two parties.

Throughout the partnership, Porton has adhered to a customer-centric service philosophy, providing Daewoong Pharma with end-to-end CMC solutions. Leveraging its experienced R&D and manufacturing teams and robust quality management system, Porton offers comprehensive support spanning toxicology batch R&D and production, API process optimization, GMP manufacturing, and IND-enabling registration support.

By consistently supplying APIs that meet stringent quality requirements, Porton has not only precisely aligned with Daewoong Pharma’s innovative drug R&D needs, but also empowered the efficient and seamless advancement of its key pipelines through professional, reliable services.

Daewoong Pharma has highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.

With years of experience in the CDMO industry, Porton has actively expanded its global layout, covering the fields from small-molecule drugs to new-molecule drugs. It is dedicated to providing customers with Speed, Commitment, Innovative, and Integration API CDMO solutions, boasting rich project delivery experience and profound technical accumulation. In the future, Porton will continue to provide full-life-cycle services for Daewoong Pharma’s key pipelines, and work hand in hand with global partners to enable earlier access to good medicines.